Home > Insider Trading > Filing (0000899243-21-003286)

Filing Details

Accession Number:: 0000899243-21-003286
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-26 16:05:09
Reporting Period:: 2021-01-26

Accepted Time:: 2021-01-26 16:05:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1731831	Eidos Therapeutics Inc.	EIDX	Pharmaceutical Preparations (2834)	463733671

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1743881	Bridgebio Pharma, Inc.	421 Kipling Street Palo Alto CA 94301		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-01-26	14,428,836	$0.00	1,000	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Footnotes

On January 26, 2021, pursuant to the Agreement and Plan of Merger, dated as of October 5, 2020 (the "Merger Agreement"), by and among BridgeBio Pharma, Inc. ("BridgeBio"), Eidos Therapeutics, Inc. ("Eidos"), Globe Merger Sub I, Inc. ("Merger Sub I") and Globe Merger Sub II, Inc. ("Merger Sub II"), Merger Sub I merged with and into Eidos (the "Initial Merger"), with Eidos surviving the Initial Merger, and thereafter Eidos merged with and into Merger Sub II (the "Subsequent Merger" and, together with the Initial Merger, the "Mergers"), with Merger Sub II surviving the Subsequent Merger as an indirect and wholly owned subsidiary of BridgeBio under the name "Eidos Therapeutics, Inc." (the "Surviving Corporation").
(Continued from footnote 1) At the Effective Time, each share of common stock, par value $0.001 per share, of Eidos ("Eidos Common Stock") issued and outstanding immediately prior to the Effective Time (subject to certain exceptions) was converted into the right to receive, at the election of each stockholder of Eidos, (A) 1.85 shares of BridgeBio's common stock ("BridgeBio Common Stock"), par value $0.001 per share (the "Stock Consideration"), or (B) $73.26 in cash (the "Cash Consideration"). As of the Effective Time, all shares of Eidos Common Stock issued and outstanding immediately prior to the Effective Time were cancelled, and all shares of Merger Sub I held by BridgeBio Pharma LLC immediately prior to the consummation of the Initial Merger were converted into shares of the Surviving Corporation in the Mergers. As a result of the Mergers, BridgeBio now owns all of the outstanding shares of common stock of the Surviving Corporation.
Calculation of number of shares give effect to the consummation of the Initial Merger described herein, in which shares of Eidos Common Stock issued and outstanding immediately prior to the Effective Time were cancelled and the 1,000 shares of Merger Sub I held by BridgeBio were converted into an aggregate of 1,000 shares of common stock of the Surviving Corporation.